BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35995822)

  • 1. Four-copy number alteration (CNA)-related lncRNA prognostic signature for liver cancer.
    Cheng Z; Guo Y; Sun J; Zheng L
    Sci Rep; 2022 Aug; 12(1):14261. PubMed ID: 35995822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
    Zhao QJ; Zhang J; Xu L; Liu FF
    World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
    Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
    BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
    Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
    Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
    PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
    Fan CN; Ma L; Liu N
    J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis of ceRNA network reveals potential prognostic Hint1-related lncRNAs involved in hepatocellular carcinoma progression.
    Zhang C; Bao T; Ke Y; Liu X; Wang X; Liao W; He Y; Wang L
    World J Surg Oncol; 2022 Mar; 20(1):67. PubMed ID: 35241097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer.
    Zhong W; Wang D; Yao B; Chen X; Wang Z; Qu H; Ma B; Ye L; Qiu J
    J Zhejiang Univ Sci B; 2021 Aug; 22(8):664-681. PubMed ID: 34414701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.
    Hu X; Wu L; Liu B; Chen K
    Front Immunol; 2021; 12():651056. PubMed ID: 34122409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eight-lncRNA signature of cervical cancer were identified by integrating DNA methylation, copy number variation and transcriptome data.
    Zhong Q; Lu M; Yuan W; Cui Y; Ouyang H; Fan Y; Wang Z; Wu C; Qiao J; Hang J
    J Transl Med; 2021 Feb; 19(1):58. PubMed ID: 33557879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic identification of lncRNA-based prognostic biomarkers for glioblastoma.
    Li M; Long S; Hu J; Wang Z; Geng C; Ou S
    Aging (Albany NY); 2019 Nov; 11(21):9405-9423. PubMed ID: 31692451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of significant biomarkers related with prognosis of liver cancer by lncRNA-associated ceRNAs analysis.
    He J; Zhao H; Deng D; Wang Y; Zhang X; Zhao H; Xu Z
    J Cell Physiol; 2020 Mar; 235(3):2464-2477. PubMed ID: 31502679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
    Lai C; Wu Z; Li Z; Yu H; Li K; Tang Z; Liu C; Xu K
    Cancer Med; 2021 Sep; 10(18):6534-6545. PubMed ID: 34374227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.